COVID-19-Related Healthcare Resource Utilisation and Costs in Paediatric Patients in Germany: A Population-Based Study
COVID-19-associated HCRU and costs among the paediatric population in Germany are non-negligible, driven largely by hospitalisations, particularly those who had a critical care admission and were at high risk.
Authors
- Hannah R. Volkman (ORCID: https://orcid.org/0000-0001-7274-9641)
- Kiran K Rai (ORCID: https://orcid.org/0000-0002-3250-0275)
- Jennifer L. Nguyen (ORCID: https://orcid.org/0000-0002-4064-0227)
- Lucy Massey (ORCID: https://orcid.org/0000-0003-0394-2303)
- A Schmetz (ORCID: https://orcid.org/0000-0001-6436-9382)
- Hannah Gowman (ORCID: https://orcid.org/0009-0008-0347-4670)
- Jingyan Yang
- Monica Seif (ORCID: https://orcid.org/0000-0002-2170-1522)
Institutions
- Pfizer (United States) (US)
- Adelphi Group (United Kingdom) (GB)
- BioNTech (Germany) (DE)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-08-11
- DOI
- https://doi.org/10.1007/s12325-025-03313-5
- Primary Topic
- Child and Adolescent Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00